Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1601

2.
3.

Varenicline: a first-line treatment option for smoking cessation.

Garrison GD, Dugan SE.

Clin Ther. 2009 Mar;31(3):463-91. doi: 10.1016/j.clinthera.2009.03.021. Review.

PMID:
19393839
4.
5.
6.

Varenicline for smoking cessation: a placebo-controlled, randomized study.

Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S.

Respirology. 2009 Apr;14(3):384-92. doi: 10.1111/j.1440-1843.2008.01476.x. Epub 2009 Feb 20.

PMID:
19192221
7.
8.

Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study.

Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, Park PW, Chopra P.

Clin Ther. 2011 Apr;33(4):465-77. doi: 10.1016/j.clinthera.2011.04.013.

PMID:
21635992
9.

Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, Anziano R, Reeves K.

Arch Intern Med. 2006 Aug 14-28;166(15):1571-7.

PMID:
16908789
10.
11.

A double-blind study evaluating the long-term safety of varenicline for smoking cessation.

Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J.

Curr Med Res Opin. 2007 Apr;23(4):793-801.

PMID:
17407636
12.

The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial.

Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, Williams KE, Billing CB Jr.

Curr Med Res Opin. 2008 Jul;24(7):1931-41. doi: 10.1185/03007990802177523 . Epub 2008 May 29.

PMID:
18513462
13.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
15.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
16.
17.

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group.

JAMA. 2006 Jul 5;296(1):47-55.

PMID:
16820546
18.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
19.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
20.

A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder.

Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, George TP.

J Clin Psychiatry. 2012 May;73(5):654-60. doi: 10.4088/JCP.11m07522. Erratum in: J Clin Psychiatry. 2012 Jul;73(7):1035.

PMID:
22697191

Supplemental Content

Support Center